<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319331</url>
  </required_header>
  <id_info>
    <org_study_id>09-0667</org_study_id>
    <nct_id>NCT01319331</nct_id>
  </id_info>
  <brief_title>The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes</brief_title>
  <official_title>The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Omni Bio Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP)&#xD;
      will preserve beta-cell function and help slow the progression of type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess participant safety &amp; feasibility of study drug administration</measure>
    <time_frame>Study duration is 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess AAT treatment on the maintenance of c-peptide production</measure>
    <time_frame>Stimulated c-peptide at year one and two.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effects of AAT on glycemic variability and A1c.</measure>
    <time_frame>Continuous Glucose Monitoring at one and two years.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Alpha-1 Antitrypsin (AAT, Aralast NP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha 1-Antitrypsin (AAT, Aralast NP)</intervention_name>
    <description>Eligible subjects will be treated once a week for 8 weeks (8 total treatments).</description>
    <arm_group_label>Alpha-1 Antitrypsin (AAT, Aralast NP)</arm_group_label>
    <other_name>Alpha-1 Antitrypsin</other_name>
    <other_name>AAT</other_name>
    <other_name>Aralast NP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Type 1 Diabetes Mellitus based on ADA Criteria for fewer than 5 years but&#xD;
             more than 100 days&#xD;
&#xD;
          -  6-45 years of age, inclusive. To assess safety, we will initially enroll 8 patients&#xD;
             over the age of 16. Following the last infusion of the 8th patient, we will assess&#xD;
             adverse events. As long as there are no stopping criteria met for these 8 patients we&#xD;
             will decrease the age criteria down to 6 years old.&#xD;
&#xD;
          -  C-peptide increase during screening mixed meal tolerance test with a minimal&#xD;
             stimulated value of ≥ 0.2 pmol/mL.&#xD;
&#xD;
          -  Positive for antibodies to insulin (if insulin autoantibody positive only,&#xD;
             determination must be within two weeks of insulin initiation), GAD-65, IA-2 or ZnT8&#xD;
&#xD;
          -  Agree to intensive management of diabetes with an HgbA1c goal of &lt; 7.0%&#xD;
&#xD;
          -  If female, (a) surgically sterile or (b) postmenopausal or (c) if of reproductive&#xD;
             potential, willing to use medically acceptable birth control (e.g. female hormonal&#xD;
             contraception, barrier methods or sterilization. ) until 3 months after completion of&#xD;
             any treatment period&#xD;
&#xD;
          -  If male and of reproductive potential, willing to use medically acceptable birth&#xD;
             control until 3 months after completion of any treatment period, unless the female&#xD;
             partner is postmenopausal or surgically sterile&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper limit of normal&#xD;
&#xD;
          -  AST &lt; 2 times the upper limit of normal&#xD;
&#xD;
          -  Hematology:WBC &gt; 3000 x 109/L; platelets &gt; 100 x 109/L; hemoglobin &gt; 10.0 g/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to comply with the requirements of the study protocol&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 30 kg/m2&#xD;
&#xD;
          -  Unstable blood sugar control defined as one or more episodes of severe hypoglycemia&#xD;
             (defined as hypoglycemia that required the assistance of another person) within the&#xD;
             last 30 days&#xD;
&#xD;
          -  Previous immunotherapy for T1D&#xD;
&#xD;
          -  Administration of an experimental agent for T1D at any time or use of an experimental&#xD;
             device for T1D within 30 days of screening, unless approved by the study PI&#xD;
&#xD;
          -  History of any organ transplant, including islet cell transplant&#xD;
&#xD;
          -  Active autoimmune or immune deficiency disorder (e.g. sarcoidosis, rheumatoid&#xD;
             arthritis)&#xD;
&#xD;
          -  Serum bilirubin &gt; ULN, except those subjects whose abnormal values were attributed to&#xD;
             any stable, benign condition (such as Gilbert's Syndrome) may be included&#xD;
&#xD;
          -  TSH outside the normal range at screening, except those subjects on stable doses of&#xD;
             thyroid hormone replacement therapy may be included&#xD;
&#xD;
          -  Known HIV positivity, active hepatitis B or active hepatitis C infection&#xD;
&#xD;
          -  Anticipated pregnancy during active dosing or within 3 months after completion of&#xD;
             active dosing phase&#xD;
&#xD;
          -  History of a malignant neoplasm within the previous 5 years (except in situ cervical&#xD;
             cancer and curable non-melanoma skin malignancy)&#xD;
&#xD;
          -  Any social condition or medical condition that would, in the opinion of the&#xD;
             investigator, prevent complete participation in the study or that would pose a&#xD;
             significant hazard to the subjects' participation&#xD;
&#xD;
          -  History of active substance abuse within 12 months of screening&#xD;
&#xD;
          -  A psychiatric or medical disorder that would prevent giving informed consent&#xD;
&#xD;
          -  Individuals with a history of IgA deficiency&#xD;
&#xD;
          -  Individuals with a history of hypersensitivity to AAT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Gottlieb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.barbaradaviscenter.org/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>AAT</keyword>
  <keyword>Alpha-1 Antitrypsin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

